

Triox Nano

Short profile

Triox Nano Ltd

CHARITÉ/BIH-PARTNER WANTED!
More information [here](#)

Medical field	Infectology / Virology / Laboratory Medicine
Product	TXN-D19, biochemical / Diagnostics
Growth stage	Proof of Concept
Founders	Roy Farfara (CTO), Joseph Farfara (CEO)

Description of product:

Available Elisa and PCR tests for SARS-CoV-2 are suboptimal, in term of their clinical relevance. The first taking too long to diagnose infectious patients while the other remain positive in the late phase when the patient may not be infectious anymore. Triox Nano's TXN-D19 is an easily applicable nanotechnological solution for improving the overall sensitivity and specificity of commonly used molecular and antigen based tests for diagnosis of COVID-19 in human respiratory and blood samples. The solution is based on uniquely designed nanoparticles that bind to the SARS-CoV-2 S protein RBD region with high predicted affinity ($K_d < 5$) and allow to diagnose the full viral structure in the medium.

Project goal:

Implementation of TXN-D19 in currently used molecular diagnostics protocols for CoVID-19 will increase sensitivity and specificity by enabling detection of low-abundance carries at early stages of infection, consequently leading to faster eradication of SARS-CoV-2 transmission chains, and perhaps a better clinical outcomes.

Project type:

Evaluation of the ability of TXN-D19 to enhance the analytical sensitivity and specificity of real-time PCR based molecular diagnostics tests for Covid-19 using archived samples of confirmed COVID-19 cases and other respiratory virus diseases as well as prospectively evaluating samples of patients with typical symptoms.

Estimated Time for Validation: 1 year.

€ Eligible by the IIA

✉ roy@trioxnano.com

📞 Roy Farfara
+972587127700

🌐 www.smartriox.com

International Health-Tech

Pilot Program with

**World-Leading
Hospitals**